Sichuan Cunde Therapeutics

Cunde Therapeutics is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, focused on the discovery and development of innovative small molecule drugs for metabolic diseases. As the R&D arm of the Sichuan Cunde Pharmaceutical group, the company specializes in creating oral alternatives to traditional injectable peptide therapies, specifically targeting the GLP-1 and GIP pathways. Its lead program, CD-001, is a potent and selective oral small molecule GLP-1 receptor agonist currently undergoing Phase 1 clinical evaluation for the treatment of type 2 diabetes and obesity. Cunde Therapeutics leverages its internal medicinal chemistry expertise to develop a pipeline of multi-receptor agonists aimed at addressing unmet needs in endocrinology and hepatology.